Gestione MGUS da parte del medico di medicina generale

Barra laterale dell'articolo

PDF
Pubblicato: mar 31, 2024
DOI: https://doi.org/10.30459/2024-7
Parole chiave:
MGUS, Medicina Generale MGUS, General medicine

Contenuto principale dell'articolo

Anna Rita Varani
Medico medicina generale Asl Rm 1
Maria Elisabetta Perrone
Corsista formazione triennale in medicina Generale

Abstract

Il termine gammopatie monoclonali comprende un insieme di quadri ematologici, potenzialmente benigni o maligni, caratterizzati da un disordine proliferativo delle plasmacellule a livello del midollo osseo e accumulo di immunoglobuline monoclonali o parti di esse (proteina M) nel siero, urine, o raramente organi interni.
Il processo potrebbe originare durante la maturazione antigene-dipendente dei linfociti B e delle plasmacellule.


Durante questi eventi fisiologici possono verificarsi traslocazioni che coinvolgono oncogeni dei geni codificanti per le catene leggere o pesanti delle immunoglobuline, determinando così l’instabilità genetica responsabile della patogenesi della discrasia e della monoclonalità delle immunoglobuline.

Downloads

I dati di download non sono ancora disponibili

Dettagli dell'articolo

Come citare
[1]
Varani, A.R. e Perrone, M.E. 2024. Gestione MGUS da parte del medico di medicina generale. Italian Journal of Prevention, Diagnostic and Therapeutic Medicine. 7, 1 (mar. 2024), 51-55. DOI:https://doi.org/10.30459/2024-7.
Fascicolo
V. 7 N. 1 (2024): Ital. J. Prev. Diagn. Ther. med.
Sezione
Ricerca Società Conoscenza Formazione
Creative Commons License

Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.

Riferimenti bibliografici

Brown LM (2008). Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 111:3388-3394.

Alexander DD (2007). Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 120 (suppl 12):40-61.

Kyle RA (2006). Prevalence of Monoclonal Gammopathy of Undetermined Significance. NEJM. 354:1362-1369 .

Ronald S Go (2017). How I manage monoclonal gammopathy of undetermined significance . Blood. 131(2).

Kyle RA (1978). Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 64:814-826.

Landgren O (2017). Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey . Blood Cancer j. 7(10):e 618.

Landgren O (2014). Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 28 (7).

Vachom CM (2009). Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 114(4):785-90.

Schroeder ,Cl. Biochemistry, 2023.

International Myeloma Working Group (2003) Br.J.haematol. 121:749-7579.

Kyle RA et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance . N eng j med . 346(8):564-9.

Vaxman I (2020) When to Suspect a Diagnosis of Amyloidosis. Acta Haematol . 143(4):304-311.

Gertz MA (2020). Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. Jul 7;324(1):79-89.

Amyloidosis Support Group, 4th International ATTR Amyloidosis Meeting. Category: External Event 03-2023 .

Amyloidosis Support Group, 4th International ATTR Amyloidosis Meeting. Category: External Event 03-2023

Angioi A (2023). Classification and management of MGRS related diseases. G Ital Nefrol. 40(Suppl 81): 2023-S81.

Gnanasampanthan S (2023). Monoclonal gammopathies of renal significance. Clinical Medicine Journal. 23(3):250-253.

European Myeloma Network(2014). European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Feb;99(2):232-42.

Rao M (2012). Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs: Identification of Future Research Needs From Comparative. Free Books & Documents. Report No.: 12-EHC135-EF.

Mangiacavalli S (2013). Monoclonal gammopathy of undetermined significance: a new proposal of workup .Eur.J.Haemat. 91(4):356-60.

Mouhieddine TH (2019). Monoclonal gammopathy of undetermined significance.Blood. 133(23):2484-2494 .

Bruehl F.K (2023). IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders. Haematologica. Vol. 108 No. 10 (2023): October.

Linfeng LI (2023). Nutritional Status Indices and Monoclonal Gammopathy of Undetermined Significance Risk in the Elderly Population: Findings from the National Health and Nutrition Examination Survey. Nutriens . 15(19), 4210.